Publications by authors named "Schofer J"
Background: Transcatheter tricuspid valve intervention (TTVI) has been increasingly adopted in recent years for the treatment of patients with tricuspid regurgitation (TR). However, no dedicated risk stratification has been established for patients undergoing TTVI.
Objectives: The aim of the present study was to propose a dedicated risk score for patients affected by severe TR undergoing TTVI.
Article Synopsis
- Doctors are studying how a procedure called transcatheter tricuspid valve interventions (TTVI) affects patients with heart issues, specifically focusing on something called mitral regurgitation (MR) after the procedure.
- They looked at data from a big group of patients and found that many showed improvement in MR after the procedure, but some got worse.
- They discovered that certain factors, like successful procedures and specific treatments, could help predict whether a patient’s MR would improve or get worse after TTVI.
Article Synopsis
- * It found that patients with mild residual TR had an 85% survival rate, while those with moderate and severe TR had significantly lower rates of 70% and 44%, respectively.
- * The research emphasizes the need for a more detailed classification of TR severity to better predict patient outcomes and highlights the goal of achieving at least mild to moderate residual TR for successful interventions.
This paper analyzes and compares patterns of U.S. domestic rail freight volumes during and after the disruptions caused by the 2007-2009 Great Recession and the COVID-19 pandemic in 2020.
View Article and Find Full Text PDFArticle Synopsis
- The study examines the effectiveness of the TRI-SCORE in predicting outcomes for patients undergoing transcatheter tricuspid valve intervention (TTVI), using data from a large, international registry called TriValve.
- Among the 634 patients analyzed, those with a TRI-SCORE of 8 or higher were found to have a significantly increased risk of all-cause mortality and complications within 30 days of the procedure, compared to those with lower TRI-SCOREs.
- Despite indicating a higher risk for severe outcomes, the TRI-SCORE overall showed limited effectiveness in predicting clinical results following TTVI, as improvements in patient functional class were observed across all TRI-SCORE levels.
Aims: T-TEER is an effective therapy for the treatment of tricuspid regurgitation (TR). However, the effects of leaflets clipping on tricuspid valve annulus (TA) have not been investigated in detail. The aim of this study is to investigate the effects of tricuspid transcatheter edge-to-edge repair (T-TEER) on TA diameter.
View Article and Find Full Text PDFArticle Synopsis
- A recent study evaluated the effectiveness of second-generation carotid stents (SGS) compared to traditional single-layer stents and carotid endarterectomy (CEA), finding that SGS can lead to better outcomes in certain cases.
- Data from over 100,000 patients indicated that specific SGS designs, like Casper/Roadsaver and CGuard, significantly reduced the risk of death, stroke, and myocardial infarction compared to CEA, while Gore stent outcomes were generally poorer.
- Overall, the findings suggest that certain SGS types may offer advantages over CEA, but the performance varies by stent design, highlighting the need for cautious interpretation and consideration of individual patient circumstances.
Article Synopsis
- The study aimed to compare the characteristics and outcomes of patients with atrial STR (ASTR) and ventricular STR (VSTR) who underwent transcatheter edge-to-edge repair (T-TEER) for tricuspid regurgitation (TR).
- Patients were categorized into ASTR or VSTR based on specific cardiac criteria, and a total of 298 were included in the analysis, with similar procedural success rates for both groups.
- Results showed that while T-TEER effectively reduced TR in both ASTR and VSTR patients, survival rates at 12 months were significantly higher for ASTR (91%) compared to VSTR (72%).
Article Synopsis
- Transcatheter aortic valve replacement (TAVR) for severe native aortic valve regurgitation has shown suboptimal outcomes, particularly with older valve technologies; this study evaluates newer devices.
- The PANTHEON study analyzed 201 patients who received TAVR with both self-expanding and balloon-expandable valves, focusing on success rates and health outcomes after one year.
- Results revealed that while technical success was high, issues like transcatheter valve embolization occurred in a significant number of cases, indicating that TAVR still poses challenges despite advancements in valve technology.
Objectives: The authors sought to evaluate the incidence, predictors, and outcomes of new permanent pacemaker implantation (PPI) after transcatheter aortic valve replacement (TAVR) with contemporary self-expanding valves (SEV).
Background: Need for PPI is frequent post-TAVR, but conflicting data exist on new-generation SEV and on the prognostic impact of PPI.
Methods: This study included 3,211 patients enrolled in the multicenter NEOPRO (A Multicenter Comparison of Acurate NEO Versus Evolut PRO Transcatheter Heart Valves) and NEOPRO-2 (A Multicenter Comparison of ACURATE NEO2 Versus Evolut PRO/PRO+ Transcatheter Heart Valves 2) registries (January 2012 to December 2021) who underwent transfemoral TAVR with SEV.
Background: The real-world outcomes of the use of the BASILICA (Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery Obstruction) transcatheter technique in Europe have not been described.
Aims: We sought to evaluate the procedural and one-year outcomes of BASILICA in patients at high risk for coronary artery obstruction (CAO) undergoing transcatheter aortic valve implantation (TAVI) in a multicentre European registry (EURO-BASILICA).
Methods: Seventy-six patients undergoing BASILICA and TAVI at ten European centres were included.
Article Synopsis
- This study examines the relationship between tricuspid valve gradient (TVG) and clinical outcomes in patients who underwent tricuspid transcatheter edge-to-edge repair (TEER) for significant tricuspid regurgitation.
- Researchers analyzed data from 308 patients and categorized them into quartiles based on their mean TVG at discharge.
- The results showed no significant differences in mortality or heart failure hospitalizations across the TVG quartiles one year post-procedure, indicating that higher discharge TVG was not linked to worse outcomes.
Background: In recent years, transcatheter aortic valve replacement (TAVR) techniques and technology have continuously improved. Data regarding the impact of these advancements on outcomes in large real-world settings are still limited. The aim of this study was to investigate temporal trends and assess contemporary outcomes after TAVR with Evolut PRO/PRO+ supra-annular self-expanding valves.
View Article and Find Full Text PDFAims: The impact of sexuality in patients with significant tricuspid regurgitation (TR) undergoing transcatheter tricuspid valve intervention (TTVI) is unknown. The aim of this study was to investigate sex-specific outcomes in patients with significant TR treated with TTVI vs. medical therapy alone.
View Article and Find Full Text PDFPERFORMANCE 1 study: Novel carotid stent system with integrated post-dilation balloon and embolic protection device.
Catheter Cardiovasc Interv
November 2022
Objectives: The PERFORMANCE I study was designed to evaluate the safety and feasibility of the Neuroguard IEP® System, a novel carotid stent system with an integrated embolic filter and post-dilatation balloon, to treat clinically significant carotid artery stenosis.
Background: The risk of major adverse events during carotid artery stenting is comparable to carotid endarterectomy, however, the risk of minor stroke remains higher with stenting.
Methods: In total, 67 patients undergoing carotid artery stenting were enrolled at nine centers in Europe.
Background: The ACURATE neo2 (NEO2) and Evolut PRO/PRO+ (PRO) bioprostheses are new-generation self-expanding valves developed for transcatheter aortic valve replacement (TAVR).
Aims: We sought to compare the performance of the ACURATE neo2 and Evolut PRO/PRO+ devices.
Methods: The NEOPRO-2 registry retrospectively included patients who underwent TAVR for severe aortic stenosis with either the NEO2 or PRO devices between August 2017 and December 2021 at 20 centres.
Background: Single-cohort studies suggest that second-generation stents (SGS; “mesh stents”) may improve carotid artery stenting (CAS) outcomes by limiting peri- and postprocedural cerebral embolism. SGS differ in the stent frame construction, mesh material, and design, as well as in mesh-to-frame position (inside/outside). Objectives: To compare clinical outcomes of SGS in relation to first-generation stents (FGSs; single-layer) in CAS.
View Article and Find Full Text PDFArticle Synopsis
- Severe prosthesis-patient mismatch (PPM) is linked to negative outcomes after transcatheter aortic valve replacement (TAVR), and this study investigates its effects in patients undergoing a second TAVR (TAV-in-TAVR).
- The study analyzed data from 155 patients across 28 centers, finding that 6.5% experienced severe PPM and 14.2% moderate PPM, with higher rates in specific TAVR types.
- Results showed that severe PPM correlated with increased one-year all-cause mortality and worsened symptoms, although many patients saw improvement after receiving a new valve to treat the mismatch.
Background: Transcatheter aortic valve replacement (TAVR) with the ACURATE neo device has been associated with a non-negligible incidence of paravalvular aortic regurgitation (AR). The new-generation ACURATE neo2 has been designed to mitigate this limitation.
Aims: The aim of the study was to compare TAVR with the ACURATE neo and neo2 devices.
Resilience of U.S. Rail Intermodal Freight during the Covid-19 Pandemic.
Res Transp Bus Manag
June 2022
The rapid onset of the COVID-19 pandemic in March 2020 marked a challenging time for the US and its freight industry. Manufacturing slowed, consumer purchasing patterns changed, and for many, shopping moved online. The freight industry suffered a sharp decline in shipments, followed by a surprisingly quick rebound.
View Article and Find Full Text PDFObjectives: This study evaluated the incidence, management, and outcome of patients who experienced MitraClip (Abbott Vascular) failure secondary to loss of leaflet insertion (LLI), single leaflet detachment (SLD), or embolization.
Background: Transcatheter edge-to-edge repair with MitraClip is an established therapy for the treatment of mitral regurgitation (MR), but no data exist regarding the prevalence and outcome according to the mode of clip failure.
Methods: Between January 2009 and December 2020, we retrospectively screened 4,294 procedures of MitraClip performed in 19 centers.
Article Synopsis
- The study examined the relationship between right ventricular (RV) and pulmonary arterial (PA) function, focusing on how effectively the RV works against the pressure in the PA in patients with tricuspid regurgitation (TR) undergoing valve repair or replacement.
- Researchers measured the RV-PA coupling ratio by using echocardiograms before and after the procedure, with a key focus on the impact of this ratio on 1-year mortality.
- Findings showed that a higher RV-PA coupling ratio was linked to lower mortality rates, indicating that improved RV function is crucial for better outcomes post-surgery in patients with TR.
Background: Late Stanford type A aortic dissections (TAADs) are a very rare complication after transcatheter aortic valve implantation (TAVI). Surgery is the treatment of choice, but perioperative mortality (25%) and neurological complications (18%) remain high.
Case Summary: An 85-year-old male patient presented with acute chest pain 5 months after a transfemoral Evolut R 34 mm transcatheter heart valve (THV) implantation.